Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P21675
UPID:
TAF1_HUMAN
Alternative names:
Cell cycle gene 1 protein; TBP-associated factor 250 kDa; Transcription initiation factor TFIID 250 kDa subunit
Alternative UPACC:
P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1; Q70Q86; Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03
Background:
Transcription initiation factor TFIID subunit 1, also known as TAF1, plays a pivotal role in the initiation of RNA polymerase II-dependent transcription. It is a core component of the TFIID complex, essential for recognizing and binding promoters, facilitating the assembly of the pre-initiation complex. TAF1's unique kinase domains enable it to phosphorylate various transcription factors, including TP53, influencing cell cycle progression.
Therapeutic significance:
TAF1's involvement in X-linked dystonia-parkinsonism and intellectual developmental disorder underscores its potential as a therapeutic target. Understanding TAF1's role could pave the way for innovative treatments for these neurological conditions.